NovaDDE Plus is now live!
Built for scientists who use AI for drug discovery every day — more compute, priority access, concurrent runs, API access, and end-to-end campaign execution.
$30/month and sign up by September 25 to get your first month free.
Our goal is simple: put the most powerful AI for drug discovery into the hands of every scientist.
Novartis halted development of an experimental drug it hoped would treat amyotrophic lateral sclerosis, or Lou Gehrig’s disease, the latest in a long history of failed efforts to find a cure for the deadly condition.
Novartis shareholder Artisan Partners said the Swiss drugmaker needs to shake up its board and improve its dealmaking after its shares plunged following three major clinical trial setbacks, Reuters reported.
Novartis shares tanked 10% on Tuesday after the pharmaceutical giant said its del-desiran drug for muscle-wasting disorder failed in a late-stage trial, its third drug trial setback in a week.
Check out CNBC's analysis of this breaking story: